Pathophysiology of Acquired Bone Marrow Failure

Read full text Summarise with VIRAT
Authors: Nicholas C. Lee, Neal S. Young
Cited by: 0
References: 242

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Aplastic anemia (AA) exemplifies immune-mediated bone marrow failure, presenting with pancytopenia, hypocellular marrow, and profound loss of hematopoietic stem-progenitor cells. Clinical success of antithymocyte globulin plus cyclosporine and allogeneic transplantation, the necessity for conditioning in syngeneic grafts, and dependence on long-term calcineurin inhibition implicate cytotoxic T cells and their cytokines (IFN-γ, TNF-α) as central pathogenic drivers. Single-cell and genomic studies reveal oligoclonal, patient-specific CD8+ expansions, Th17/Treg imbalance, and frequent clonal hematopoiesis that can either permit immune escape (paroxysmal nocturnal hemoglobinuria (PNH), human leukocyte antigens (HLA) loss) or herald myeloid evolution ( RUNX1 , splicing factor, ASXL1 , monosomy 7). Short telomeres, inherited telomere repair and other germline mutations, plus inflammatory adipocyte-rich marrow, further promote genomic instability. Therapeutically, matched sibling transplantation remains curative for eligible patients; horse ATG/CsA with eltrombopag is the current first-line IST, while alternative donor, haploidentical and cord blood transplants, JAK inhibition, and TPO mimetics expand options for refractory disease.

Fields of Study & Subjects

Hematopoietic Stem Cell Transplantation Blood disorders and treatments Hematological disorders and diagnostics

Publication details

Journal / source
Springer eBooks
Pages
21–51
Publication date
25 March 2026
Language
EN
Document type
Book chapter